Published Paper Details:

Immediate Release Tablets (IRTs) are pivotal in pharmaceutical formulations, designed to disintegrate rapidly and release their active pharmaceutical ingredients (APIs) swiftly upon administration. This formulation approach ensures rapid onset of action, enhancing therapeutic efficacy, particularly in acute conditions. Advancements in excipient technology have significantly improved IRT performance. The incorporation of superdisintegrants such as sodium starch glycolate, croscarmellose sodium, and crospovidone has been shown to enhance the disintegration and dissolution rates of tablets, thereby improving bioavailability. Additionally, the use of co-processed excipients has optimized tablet hardness and friability, contributing to better tablet integrity and patient compliance. Formulation strategies, including the direct compression method, have been employed to streamline the manufacturing process of IRTs, reducing production costs and time. This method has been successfully utilized in the development of various IRTs, such as those containing valsartan, demonstrating satisfactory dissolution profiles and stability. Therapeutically, IRTs have proven beneficial in the management of conditions requiring rapid drug action, such as hypertension and acute pain. For instance, immediate release formulations of telmisartan have shown improved dissolution rates and bioavailability compared to conventional formulations.